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Rationale: Inflammation is a universal pathological reaction and is characterized among
other things by increased heat production. The question stays whether the contribution of
the inflamed lung tissues to the overall exhaled breath temperature (EBT) can be reliably
detected and used in everyday clinical practice.
Methods: We have designed a simple device for assessment of EBT and explored its
performance under standard indoor conditions. We made our measurements in the morning
hours, documenting the ambient conditions (room temperature, humidity, atmospheric
pressure), and physiological characteristics of the tested subjects (heart rate, blood
pressure, otic and axillary temperature). We assessed its day-to-day reproducibility in 17
healthy volunteers and its ability to discriminate between the same subjects without
respiratory disease and uncontrolled asthmatics (n ¼ 14). We also compared the EBTof the
14 asthmatics before and after anti-inflammatory treatment.
Results: No association was found between EBT and any of the ambient conditions: room
temperature, atmospheric pressure and humidity. While otic and axillary temperatures,
which were measured in parallel, maintained high correlation between each other
(Spearman’s rho ¼ 0.71, po0.01), EBT did not show meaningful association with any of
them. The EBT (1C) of asthmatics (median 35.45, range 34.12–36.09) was higher than that
of controls (34.84, 32.29–35.84), (p ¼ 0.009, Mann–Whitney U test). Anti-inflammatory
treatment brought down the EBT of the asthmatics (34.78, 33.23–36.06), (p ¼ 0.001,
Wilcoxon Signed Ranks test), while significantly improving their spirometry too.
Conclusions: Measurements of EBT with the device we constructed are not significantly
influenced by changes within the accepted range of a standard indoor environment. EBT
represents a different characteristic of the human organism than otic and axillary temperatures.
EBT is increased in uncontrolled asthmatics and decreases under anti-inflammatory treatment.
& 2007 Published by Elsevier Ltd.Published by Elsevier Ltd.
9230397; fax: +359 2 9230621.
com, , ted.popov@gmail.com (T.A. Popov).
ARTICLE IN PRESS
Evaluation of a simple, potentially individual device 2045Background nents, among which nitric oxide appears to be mostInflammation is a localized protective response elicited by
injury or destruction of tissues, which serves to destroy,
dilute or wall off (sequester) both the injurious agent and
the injured tissue.1 It is characterised in the acute form by
the classical signs of pain (dolor), heat (calor), redness
(rubor), swelling (tumor) and loss of function (functio laesa).
Histologically, it involves a complex series of events,
including dilatation of arterioles, capillaries and venules,
with increased permeability and blood flow, exudation of
fluids, including plasma proteins and leukocyte migration
into the inflammatory focus. The mere origin of the word
(from Latin: inflammatio, inflammare ¼ to set on fire)
implies a fervent, heat-producing process. Infections and/
or immunologic mechanisms may trigger the production of
heat in different disease states. The systemic response to
the invasion of the body by microbial pathogens such as
bacteria and viruses as well as by nonmicrobial, deleterious
physical and chemical insults is denoted as fever and is
associated with a complex sequence of events involving
different pyrogenic stimuli and neurogenic pathways leading
to increase in the core temperature of the body.2 This has
long being recognized as an important characteristic of
different morbid conditions and has rendered temperature
measurement and monitoring (thermometry) as an integral
part of the standard physical examination of patients.
While fever is a systemic reaction of the whole organism,
local inflammatory events fuel clinical symptoms in differ-
ent organs in acute and chronic infectious and noninfectious
diseases. Certain organs, like the joints in rheumatic
diseases, are readily accessible for physical examination
and increased local temperature can be directly assessed,
but others, like the lung and airways, are not accessible for
direct assessment. Measurement of the core body tempera-
ture in the axilla, mouth, ear or rectum may not add useful
information for the degree of inflammation in an organ like
the lung. At the same time, airway inflammation is
considered the most prominent feature of a chronic
respiratory disease with heavy burden to society and the
individual sufferers like asthma.3 The current state of
knowledge portraits this disorder as infiltration of the
airway wall and mucosa by different inflammatory cells,
whose products and activity are associated with the disease
specific characteristic of airway hyperresponsiveness, lead-
ing to recurrent episodes of airflow obstruction. The
inflammatory nature of asthma has been proven by hundreds
of studies employing invasive (bronchoscopy with biopsies
and bronchoalveolar lavage) and noninvasive (sputum
examination,4 volatile and liquid phase components of
exhaled air5) methods. Despite this sound theoretical basis,
the diagnosis and management of asthma in routine practice
are based on assessment of symptoms and lung function
measurements: spirometry with response to bronchodila-
tors, airway responsiveness to bronchoconstrictors like
metacholine, serial peak expiratory flow (PEF) measure-
ments. The reason for this derives from the deficiencies
associated with the methods for airway inflammation
assessment: bronchoscopy bears substantial discomfort and
some risk for the patients; sputum collection and examina-
tion is not possible for all subjects and the protocol is rather
time consuming; measurement of exhaled breath compo-prominent, is quite sensitive to ambient conditions and
technical confounding factors, requires further standardiza-
tion and is quite expensive for routine application. None of
the listed methods allows feasible day-to-day assessment of
the level of airway inflammation in primary healthcare and/
or by the patients themselves.
Inflammatory changes are also inherent to other acute
and chronic respiratory disorders like airway viral infections
(usually referred to as ‘‘common cold’’ and ‘‘influenza’’6)
and obstructive pulmonary disease (COPD),7 with specific
patterns of the underlying pathogenetic processes. Many of
the inflammatory mediators like TNFa, IL1, IL6, IL10 are
implicated in the complex network of signals in asthma,
COPD, viral and bacterial lung infections and sytemic fever
states.8 The role of the pyrogen TNFa in tuberculosis has also
been well demonstrated.9
It is very likely that inflammation would alter the thermal
balance of the affected tissues in respiratory diseases. The
question stays whether these changes can be reliably
detected against the background of ‘‘white noise’’ emitted
during the complex processes of heat exchange in the course
of breathing. Paredi et al.10 and Piacentini et al.11 have
measured the temperature of the exhaled breath of
asthmatics by using fast reacting temperature sensors in
conjunction with exhaled breath nitric oxide measurements.
Their approach to measure the temperature of exhaled
breath is rather sophisticated and difficult to standardize,
but still they have found a correlation between the amount
of the exhaled nitrogen oxide and some features of the
temperature recordings they did. This reinforced our long
dating idea to devise a precise, simple and reliable
thermometer to measure exhaled breath temperature
(EBT), so as to start filling in a largely unexplored area on
the map of human physiology and pathophysiology.
The present study reveals the potential of a new device
and method to measure EBT.Methods
Device and procedure
The thermometer for EBT measurement consists of two main
components: a 0.5 L silver plated flask in a metal cylinder
(thermos) and a thermal block with an in-built temperature
sensor (Fig. 1). The thermal block has high thermal capacity
and excellent heat conduction properties. When the exhaled
breath gets in the camera, it overflows the thermal block
and fills the flask. The inflow opening is with a reversion
valve which closes it during inhalation. Thus the last portion
of exhaled air, which has stayed longest in the lungs,
remains in the camera and imparts its temperature to the
thermal block. The superfluous air comes out through
outflow openings. The temperature in the camera is
assessed by measuring the resistance of the thermal sensor
by means of a digital ohm-meter. The measurement is
performed at 1min intervals and continues until no further
increment is noted. The time for reaching this thermal
equilibrium is between 5 and 10min. The thermal sensor is
calibrated in two points of the range 0–36 1C and the
measured value is extrapolated.
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Figure 1 Schematic drawing of the device for exhaled air
measurement: the device comprises a thermal chamber (1),
with an inlet tube (2) in its upper part fixed by means of a
tightening element (3) with in-built air outlet orifices (4). In the
interior of the air inlet tube (2) from top to bottom are situated
one-way valve (5) and temperature sensor (6), mounted on a
metal core (7); the sensor is linked to a reading device (8)
situated outside the chamber (1).
T.A. Popov et al.2046The technical characteristics of the device are as follows: measurement range: 20–40 1C,
 discriminating ability: 0.01 1C,
 time until equilibrium: o10min,
 Volume of the camera: 0.5 L, and
 weight: 320 g.aThe conversion formula is t ¼ [3287,923/ln (80,057*R)]273,
where t is temperature [1C], and R is resistance [Ohms]. It is
specific for the device and has been worked out in the process of
calibrating it.The air temperature in the room in which EBTwas measured
used to be in the range 18–25 1C, atmospheric pressure was
952–982mPa, and relative humidity was 22–53%. These
indoor air characteristics were recorded at the time of onsetof the procedure and along with the characteristics of
the examined subject. Subjects were instructed to hold the
device with one or two hands, to purse their lips around the
mouthpiece, and to proceed as if inflating a balloon: to
inhale freely through the nose and to exhale into the device
at a rate and depth suiting their normal tidal breathing
rhythm. The investigator measured with a stopwatch the
time elapsed from the beginning of the measurement and at
1min intervals recorded the indication of the ohm-meter of
the device. The measurement lasted until the same value
repeated itself on two consecutive measurements 1min
apart. The end value was entered into an EXCEL calculation
sheet with a formulaa converting Ohms to degrees Celsius to
yield the final result. After conclusion of the measurement,
the device was taken apart, washed with a disinfectant
solution, rinsed with water, and left to dry out at room
temperature.
Study design
We performed three different series of experiments to
evaluate:(1) dependence of the EBT measurement on ambient indoor
conditions, on other physiologic characteristic of the
tested subjects, and the reproducibility or the measure-
ments on subsequent days (‘‘Reliability study’’),(2) the discriminative capacity of the method to differenti-
ate between asthmatics and nonasthmatics (‘‘Discrimi-
native study’’), and(3) to assess potential changes in the EBT after anti-
inflammatory treatment in asthmatics (‘‘Treatment
study’’).Subjects
In accordance with the study design, two different sets of
subjects from among the personnel and patients of the
Clinic of Allergy and Asthma in Sofia were recruited for the
study after giving their informed consent:(1) Reliability study: All EBT measurements made were
pooled together and possible associations with the other
indoor air characteristics (room temperature, atmo-
spheric pressure, relative humidity) were sought.
Relationships between EBT and other individual char-
acteristics (age, gender, height, weight, pulse, systolic
and diastolic blood pressure, otic and axillary tempera-
ture) were explored separately for healthy controls and
asthmatics and for both groups together. EBT was
measured at approximately the same time on two
consecutive days in 17 nonsmoking subjects free of
respiratory disease: 4 men; 6 atopics; age [years]:
median 39, range 20–65: height [cm]: 165, 155–188;
weight [kg]: 64, 48–91; FEV1 [% predicted] 103, 90–120.
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Table 1 Characteristics of subjects with uncontrolled asthma.
No. Age (years) Gender Height (cm) Weight (kg) Atopy FEV1 (%) before Rx Treatment (Rx)
1 25 M 186 98 Y 76 ICS
2 46 F 158 54 N 65 SCS
3 28 F 162 50 N 79 ICS
4 75 M 167 62 Y 79 ICS
5 55 M 173 85 N 71 ICS
6 52 F 163 70 Y 37 SCS
7 45 M 171 75 N 41 SCS
8 47 F 167 58 Y 37 SCS
9 30 F 162 50 N 99 ICS
10 51 F 161 89 N 99 ICS
11 17 M 172 80 Y 118 ICS
12 45 F 164 75 N 72 ICS
13 52 M 176 86 N 48 SCS
14 28 M 180 77 Y 85 ICS
Median: 39 M ¼ 7 Median: 167 Median: 75 Y ¼ 6 Median: 74 ICS ¼ 5
Range: 17–75 F ¼ 7 Range: 158–186 Range: 50–98 N ¼ 8 Range: 37–118 SCS ¼ 9
Abbreviations: Y ¼ yes; N ¼ no; M ¼ males; F ¼ females; FEV1 ¼ forced expiratory volume in 1 s; ICS ¼ inhaled corticosteroids;
SCS ¼ systemic corticosteroids.
Evaluation of a simple, potentially individual device 2047(2) Discriminative study: EBT of the same 17 healthy
subjects was compared with EBT of 14 patients with
uncontrolled asthma as defined according to ‘‘level of
control’’ in the latest edition of GINA 2006.12 The
characteristics of the asthmatics are presented in
Table 1.(3) Treatment study: EBT and spirometry were assessed in
the same 14 patients with uncontrolled asthma after 1
week of anti-inflammatory treatment with inhaled
corticosteroid (ICS) or systemic steroid (SCS) as pre-
scribed by the treating physician.Statistics
Descriptive analysis was employed to characterize subjects
in the three different studies.
Reliability analysis calculating intraclass correlation coef-
ficient was used to assess the repeatability of the measure-
ments in the ‘‘Reliability study’’.
We could not demonstrate normal distribution of the EBT
results, so we resorted to nonparametric tests. Subse-
quently, we presented summarized data as median (range)
values.
Mann–Whitney U test was used to assess differences in
EBT between healthy controls and asthmatics in the
‘‘Discriminative study’’. Multiple regression analysis was
performed in the search of an association between EBT and
the variables characterizing the studies subjects (age,
gender, atopy, smoking status, asthma diagnosis, FEV1) and
the indoor environment of the laboratory (room tempera-
ture, atmospheric pressure, humidity).
Wilcoxon’s Signed Ranks test was used to assess changes
in EBT of asthmatics before and after anti-inflammatory
therapy in the ‘‘Treatment study’’.
Spearman’s nonparametric correlation coefficient rho
between EBT and otic/axillary temperature measurementswas calculated separately for the healthy controls and
asthmatics and for both of these groups as a whole.
Multiple regression analysis was performed using the
stepwise method to seek association between EBT (depen-
dent variable) and any of the measures of the ambient
conditions in the room, where the measurements were
performed: temperature, atmospheric pressure, and humid-
ity (independent variables). This same approach was applied
to identify associations with the other physiologic charac-
teristics of the subjects: age, gender, height, weight, pulse,
systolic, and diastolic blood pressure.
Two-tailed significance of 0.05 was accepted to be
statistically meaningful.
SPSS 13 software package was used for the calculations.
Results(1) Reliability study.
(2) Multiple regression analysis on all 132 measurements
made with EBT as dependent variable and room
temperature (values on separate days in the range
18–25 1C), atmospheric pressure (range 954–982) and
humidity (ranges 22–72) as independent variables, did
not pick any of the ambient conditions as significant
determinants.(3) No significant correlations were established between
EBT and the other body indices: age, gender, height,
weight, heart rate, systolic, and diastolic blood pres-
sure. Spearman’s correlation coefficient relating EBT
and otic temperature was low for the healthy
controls (rho ¼ 0.16, p40.1), the asthmatics (rho ¼
0.15, p40.1), going further down when both groups
were analyzed together (rho ¼ 0.06, p40.1). At the
same time, otic and axillary temperatures maintained
high correlation between each other (rho ¼ 0.71,
po0.01)
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Figure 2 Bland Altman plot of EBT measurements on separate
days by 17 healthy subjects. tomean, mean of two measurements
on separate days; todiff., difference between two measurements
on separate days.
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Figure 3 Exhaled breath (circles), otic (triangles), and axillary
(diamonds) temperature in healthy asthmatics (solid markers)
and controls (open markers). Median values are marked with a
solid line. Statistical analysis was made using the Mann–Whitney
U test, identifying significant difference between EBT of
T.A. Popov et al.2048(4)asthmatics and controls (p ¼ 0.009), but not between otic and
axillary temperature of the two groups (p40.1).The reproducibility of the EBT measurements at about
the same time on subsequent days in 11 healthy controls
turned out to be very high: the intraclass correlation
coefficient was 0.99. This low intra-subject variability is
demonstrated as a Bland–Altman plot on Figure 2.(5) Discriminative study.
(6) There was significant difference between EBT [1C] of
asthmatics (median 35.45, range 34.12–36.09) and
controls (34.84, 32.29–35.84), p ¼ 0.009, while no
significant difference was noted between the otic and
axillary temperature of the two groups (Figure 3).(7) Treatment study.
(8) There was a significant difference between EBT [1C] of
asthmatics before (median 35.45, range 34.12–36.09)
and after improvement under anti-inflammatory treat-
ment (34.78, 33.23–36.06), po0.001 (Figures 2, 4).Discussion
The lung serves as an interface between the internal milieu
of the organism and the ambient environment for gas, but
also for heat exchange. The latter has proven to be of great
importance in human physiology and pathophysiology, and
has been studied extensively since the middle of the last
century.13–15 In a unique, unrepeatable nowadays experi-
ment, McFadden et al.16 introduced in the airways of
healthy volunteers a tubing with seven temperature sensors
between the glottis and the subsegmental bronchus of the
right upper lobe and demonstrated that the temperature of
the underlying airway mucosa is decreased by higher
ventilation rate and lower initial temperatures of the
inspired air. It was also evident that air humidity was also
an important factor to consider in the process of warming up
of the inspired air.
Thermal balance of the airways was suspected to play an
important role in exercise-induced asthma (EIA), where cold
air, hyperventilation, and especially the combination of
these two factors provoked bronchoconstriction.17 Conver-
sely, a study on the protective effect of cromolyn sodium
suggested that this drug may exert its action by enhancing
the heat balance of the airways by unknown mechanisms.18It is generally believed nowadays, that asthmatic airways
are more vascularized and have higher blood perfusion rates
than normal airways.19,20
Paredi et al.10 dwelt upon the different rate of rise of the
EBT in asthmatics vs. controls, which they called DeoT. They
did not find a statistical difference between the absolute
temperature plateaus reached by those two groups, but still
their published data hint at a higher EBT of the asthmatics.
Later the same team reported that DeoT correlates with
bronchial blood flow (Qaw) and exhaled nitric oxide, which
gave the ground to conclude that it may reflect existing
inflammation.21 Piacentini et al.11 measured EBT in asth-
matic children and found significant correlation between
peak expiratory temperature (PET) and plateau expiratory
temperature (PLET) values and nitric oxide measurements.
Very recently, they used professionally developed laboratory
equipment to find significant differences between PLET of
asthmatic and healthy children, but not between DeoTof the
two groups.22 The device and method in these studies are
substantially different from our approach. While the fast
reacting thermocouples placed in front of the mouth of the
tested subject require stringent control of the laboratory
environment in terms of ambient air temperature and
ventilation, and extensive training of the tested subjects,
our device represents a thermally isolated chamber, which
holds an inbuilt metal core with high thermal conductivity,
to which each subsequent breath of the tested subject
imparts another quantum of energy until a heat equilibrium
(temperature plateau) with the lung/airways is reached.
The resolution of this thermometer is 0.01 1C and it allows
the subjects to breathe at their convenience, even taking
breaks to swallow or to make a verbal remarks. What we
measure most likely to corresponds to the PET measured by
Piacentini’s team.
The starting temperature of the thermal block of our
device corresponds to the temperature of the place where
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Figure 4 Outcomes in asthmatics before (solid circles) and after (open circles) anti-inflammatory treatment: (a) EBT of asthmatics
was significantly lower after effective anti-inflammatory treatment (p ¼ 0.001) and (b) FEV1 (% of predicted) of asthmatics was
significantly higher after effective anti-inflammatory treatment (po0.001).
Evaluation of a simple, potentially individual device 2049the device is kept. After each measurement, some condense
is visible on the silver-plated interior of the thermal camera.
It is due to the cooling down of the exhaled breath of the
subject before closed system reaches thermal equilibrium.
This may have some minimal effect on the duration of
the measurement, but it is not likely to affect the level
of the final thermal balance reached. The condense should
be washed away with disinfectant fluid and water and the
dissembled parts need to be disinfected and dried at room
temperature before using the device again.
With the single prototype we used in this study,
measurement times ranged between 4 and 10min. As the
time to make a measurement (to reach thermal equilibrium)
with our device differs between subjects, we anticipated
that it might be related to the rate of temperature increase
(DeoT). However, no differences emerged between the
time to reach equilibrium between asthmatics and
healthy controls. We assume that other subject character-
istics like ventilation rate, the individual pattern of the
respiratory maneuvers may play predominant role in
determining the duration of the EBT measurements with
our device.
Subjects did not require lengthy training to use the device
and did not find the procedure difficult to cope with. The
device holds the potential to be further upgraded: it can be
made still smaller, and the time for measurement could
be shortened. Its construction does not utilize expensive
materials. These features make it a suitable candidate for a
cheap (individual?) device for EBT measurement in routine
practice for purposes still to be identified.
Similarly to a PEF meter, single (point) readings of this
personal ‘‘inflammometer’’ may not be very meaningful per
se, but repeated daily measurements might help individual
asthma management. We also have anecdotal evidence that
the device displays sharp increase of the EBTat onset of viral
airway infections when no effect on armpit temperature has
been recorded. The poor correlation between EBT and otic/
axillary temperature measurements suggests that these
represent different physiological characteristics. Extensive
experiments would identify the separate applications of this
simple device for EBT measurement so that it could take aplace at the pharmacy shelves alongside the other members
of the medical thermometers family.Conclusions
The device we constructed can measure the temperature of
exhaled air in human subjects in a simple and acceptable
noninvasive and user-friendly way. The measurements made
with it are not significantly influenced by changes within the
accepted range of standard indoor environment character-
istics. EBT represents a different feature of the human
organism than the otic and axillary temperatures. EBT is
increased in uncontrolled asthmatics and decreases under
anti-inflammatory treatment. Further experiments are
warranted to find out if it can be applied as individual
device for asthmatics to assess the degree of control of their
airway inflammation. Studies in other lung diseases may
provide evidence about the validity and usefulness of the
method in other chronic and infectious pulmonary diseases.Conflict of interest
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